Research Analysts Offer Predictions for CervoMed Q3 Earnings

Key Points

• Brookline Capital Management has significantly reduced its Q3 2025 earnings per share (EPS) estimate for CervoMed to ($0.63), down from a previous forecast of ($0.34).
• CervoMed's stock has recently faced pressure, with shares dropping 6.9% and opening at $9.15 amid a market cap of $84.66 million.
• The consensus among analysts remains largely positive, with seven out of nine analysts rating the stock as a "buy" or better, indicating confidence in its prospects despite recent earnings setbacks.

CervoMed Inc. (NASDAQ:CRVO - Free Report) - Investment analysts at Brookline Capital Management decreased their Q3 2025 earnings per share (EPS) estimates for CervoMed in a research report issued on Monday, August 18th. Brookline Capital Management analyst T. Bussian now anticipates that the company will post earnings per share of ($0.63) for the quarter, down from their prior forecast of ($0.34). The consensus estimate for CervoMed's current full-year earnings is ($1.88) per share. Brookline Capital Management also issued estimates for CervoMed's Q4 2025 earnings at ($0.78) EPS and FY2025 earnings at ($2.65) EPS.

Several other equities analysts also recently weighed in on the company. Chardan Capital reiterated a "buy" rating and set a $15.00 target price on shares of CervoMed in a research report on Monday, August 11th. Canaccord Genuity Group raised their price objective on CervoMed from $21.00 to $27.00 and gave the stock a "buy" rating in a report on Tuesday, July 29th. D. Boral Capital raised their price objective on CervoMed from $15.00 to $31.00 and gave the stock a "buy" rating in a report on Monday, August 18th. Finally, Roth Capital restated a "buy" rating and issued a $16.00 price objective (down from $20.00) on shares of CervoMed in a report on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $23.71.

CervoMed Stock Performance

NASDAQ CRVO traded down $0.09 during trading hours on Wednesday, hitting $9.13. 178,419 shares of the company's stock were exchanged, compared to its average volume of 818,804. The business's 50 day moving average is $7.92 and its 200-day moving average is $7.44. CervoMed has a 12-month low of $1.80 and a 12-month high of $20.63. The firm has a market capitalization of $84.45 million, a P/E ratio of -3.50 and a beta of -0.79.

CervoMed (NASDAQ:CRVO - Get Free Report) last released its earnings results on Friday, August 8th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.13). CervoMed had a negative return on equity of 59.15% and a negative net margin of 290.72%.The business had revenue of $1.76 million for the quarter, compared to analysts' expectations of $1.45 million.

Institutional Trading of CervoMed

Hedge funds have recently made changes to their positions in the stock. Woodline Partners LP bought a new stake in shares of CervoMed in the 4th quarter worth approximately $175,000. Rhumbline Advisers lifted its holdings in shares of CervoMed by 35.5% in the 1st quarter. Rhumbline Advisers now owns 5,830 shares of the company's stock worth $53,000 after purchasing an additional 1,526 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in shares of CervoMed in the 4th quarter worth approximately $32,000. Citizens Financial Group Inc. RI bought a new stake in CervoMed during the 1st quarter valued at $244,000. Finally, Nuveen Asset Management LLC raised its stake in CervoMed by 113.6% during the 4th quarter. Nuveen Asset Management LLC now owns 41,569 shares of the company's stock valued at $97,000 after acquiring an additional 22,104 shares in the last quarter. Institutional investors own 25.15% of the company's stock.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.